PTC Therapeutics (PTCT) Reports Q1 Loss Per Share of $1.15

PTC Therapeutics (NASDAQ: PTCT) reported Q1 EPS of ($1.15), may not compare to the analyst estimate of ($1.20). Revenue for the quarter came in at $7.48 million versus the consensus estimate of $2.97 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Evercore lifts Ciena rating on AI-driven optical networking boom
• BMO Capital Reiterates Market Perform Rating on Axalta Coating Systems (AXTA)